ライフサイエンスコーパス: P

1 tosis/necrosis and phosphorylated-cAbl (cAbl-p).

2 or cause of early-onset Parkinson's disease (PD).

3 disease.See related article by Gonda et al., p.

4 apomorphine were active in models of AD and PD.

5 ance over 1, 2, and 4 years in patients with PD.

6 nts and patients with dissection, right CCA (p = 0.000), ICA (p = 0.001), ECA (p = 0.004) diameters,

7 significantly more effaced basilar cisterns (p = 0.0008).

8 betes (HR 2.39, P = 0.01), albumin (HR 0.35, P = 0.001), and GRS score >0.597 (HR 2.30, P = 0.04) wer

9 with dissection, right CCA (p = 0.000), ICA (p = 0.001), ECA (p = 0.004) diameters, total CCA (p = 0.

10 .001), ECA (p = 0.004) diameters, total CCA (p = 0.001), ICA (p = 0.009), and ECA (p = 0.003) diamete

11 west of 7% (20/284) after refresher in 2017 (p = 0.001), increased again to an average of 9.6% (240/2

12 reliability and accuracy were all the same (p = 0.001).

13 g characteristic-area under the curve: 0.77; P = 0.001).

14 vely, compared to those in the other cities (P = 0.001).

15 for NO2, PM10, and SO2 (1.066 [1.027, 1.107; p = 0.001], 1.044 [1.007, 1.082; p = 0.017], and 1.190 [

16 nset (RR per year 0.983; 95% CI 0.968-0.998; p = 0.002 for trend).

17 serum aldosterone were 6.8 vs. 5.5 ng/mL/h (p = 0.002) and 654 vs. 473 pg/mL (p = 0.01), respectivel

18 sed treatment (60% [12/20] vs 86% [214/248], P = 0.002) and for those on DTG-based treatment (61/92 [

19 optimal cut-off value was 1039 (AUC: 0.801; P = 0.002).

20 range [IQR], 17-41] vs. 60 min [IQR, 45-60], P = 0.002).

21 l CCA (p = 0.001), ICA (p = 0.009), and ECA (p = 0.003) diameters were also found to be different.

22 own TMIE versus 12.4% after Ivor Lewis TMIE (P = 0.003).

23 right CCA (p = 0.000), ICA (p = 0.001), ECA (p = 0.004) diameters, total CCA (p = 0.001), ICA (p = 0.

24 ) and more likely to have diabetes mellitus (p = 0.004), hypertension, hyperlipidemia, and chronic ki

25 relative to baseline, >=10%; accuracy, 82%; P = 0.004).

26 tly correlated with tumor volume (R = 0.903, P = 0.005) and MCT 1 (R = 0.85, P = 0.032) and HIF1alpha

27 mmHg (95% confidence interval [CI], 1.4-7.3; P = 0.005) and mean increase in IOP outside office hours

28 onary arterial pressure (-6.5 +/- 1.8 mm Hg; p = 0.005) and tended to decrease pulmonary vascular res

29 naptic plasticity in this mouse model of AD (P = 0.007 to untreated APP/PS1).

30 7, p = 0.020; contralateral side, r = 0.627, p = 0.007) and the Oswestry disability index scores in L

31 , 0.3) to 2.8 (SD, 0.2) on the EDTSES score (P = 0.007).

32 .004) diameters, total CCA (p = 0.001), ICA (p = 0.009), and ECA (p = 0.003) diameters were also foun

33 2.0; 95% confidence interval (CI), 1.2-3.4, P = 0.009), coronary artery disease (OR, 1.9; 95% CI, 1.

34 tio [HR] 2.54, P = 0.02), diabetes (HR 2.39, P = 0.01), albumin (HR 0.35, P = 0.001), and GRS score >

35 5 ng/mL/h (p = 0.002) and 654 vs. 473 pg/mL (p = 0.01), respectively.

36 h of stay (3 consecutive days: 0.46 d fewer, p = 0.010; 2 consecutive days: 0.77 d fewer, p < 0.001;

37 D >=4,000 mg/m(2) and radiotherapy <40 Gray (P = 0.012).

38 office hours of 2.7 mmHg (95% CI, 0.61-4.7; P = 0.013) than the lowest quintile, which were signific

39 027, 1.107; p = 0.001], 1.044 [1.007, 1.082; p = 0.017], and 1.190 [1.146, 1.235; p < 0.001], respect

40 lteplase dose was statistically significant (p = 0.018).

41 6.3% (37/591) after the start of mentorship (p = 0.019).

42 CI): 266 (77, 455) nmol.min-1.kg-1.180 min; P = 0.01; eta2p = 0.44].

43 ges from mucus in two phyla (Proteobacteria [p = 0.01] and Actinobacteria [p = 0.02]) and two familie

44 axellaceae [p < 0.001] and Pseudomonadaceae [p = 0.01]).

45 primary diagnosis of pneumonia (41% vs 28%; p = 0.02) and less often asthma (8% vs 23%; p < 0.01).

46 e and a mean +0.26-g/dL (95% CI: 0.04, 0.48; P = 0.02) increase in hemoglobin but no effect on anthro

47 Male sex (hazard ratio [HR] 2.54, P = 0.02), diabetes (HR 2.39, P = 0.01), albumin (HR 0.3

48 difference, 1.0 mmHg; 95% CI, 0.2-1.8 mmHg; P = 0.02).

49 LG co-contraction (affected side, r = 0.557, p = 0.020; contralateral side, r = 0.627, p = 0.007) and

50 s higher with PN vs. Controls (12.5% vs. 0%, p = 0.024).

51 mortality (HR: 8.027; 95% CI: 2.387-18.223; P = 0.026) and optimal cut-off value was 1039 (AUC: 0.80

52 f 69.7 (21.2) and 60.7 (26.3), respectively (p = 0.029).

53 roteobacteria [p = 0.01] and Actinobacteria [p = 0.02]) and two families (Moraxellaceae [p < 0.001] a

54 cess measure (0.22 SD; 95% CI, 0.05 to 0.38; P = 0.03), but this could not be attributed conclusively

55 sttraumatic stress disorder (52.4% vs 37.1%; p = 0.03).

56 l (i.e. increased Stop-signal reaction time; p = 0.031 and p = 0.053 respectively).

57 (R = 0.903, P = 0.005) and MCT 1 (R = 0.85, P = 0.032) and HIF1alpha expression (R = 0.83, P = 0.043

58 roup difference (95% CI): 1.89 (0.18, 3.60); P = 0.03; eta2p = 0.29] and skeletal muscle uptake of gl

59 months (95% confidence interval 20.3-45.7), P = 0.03].

60 , P = 0.001), and GRS score >0.597 (HR 2.30, P = 0.04) were independent predictors of de novo HCC.

61 ry artery disease (OR, 1.9; 95% CI, 1.1-3.7; P = 0.04), and respiratory failure (OR, 4.7; 95% CI, 1.1

62 ectively (age trend P < 0.05 and interaction P = 0.041).

63 = 0.032) and HIF1alpha expression (R = 0.83, P = 0.043).

64 on in GCF was associated with GDM (RR: 1.19; P = 0.045; CI 95% 1.00 to 1.40; and RR: 1.20; P = 0.063;

65 piratory failure (OR, 4.7; 95% CI, 1.1-26.3; P = 0.049).

66 : 4266 (261, 8270) mumol.min-1.kg-1.180 min; P = 0.04; eta2p = 0.31] and branched-chain amino acids (

67 sed Stop-signal reaction time; p = 0.031 and p = 0.053 respectively).

68 ated with NO2 and PM10 (1.044 [0.998, 1.092; p = 0.059] and 1.008 [0.966, 1.052; p = 0.702], respecti

69 = 0.045; CI 95% 1.00 to 1.40; and RR: 1.20; P = 0.063; CI 95% 0.99 to 1.45 in the adjusted model).

70 onary vascular resistance (-83 +/- 33 dynes; p = 0.07).

71 the model (likelihood-ratio statistic: 2.81, P = 0.094), providing an accurate prediction for almost

72 similar between groups (O:E = 0.65 vs 1.00, P = 0.11 and O:E = 0.79 vs 1.00, P = 0.15, respectively)

73 V complete visualization rates (p = 0.30 and p = 0.14).

74 65 vs 1.00, P = 0.11 and O:E = 0.79 vs 1.00, P = 0.15, respectively).

75 p = 0.34) or major bleeding (3.6% vs. 1.6%, p = 0.18).

76 or ER and esophagectomy were 53% versus 61% (P = 0.3), respectively.

77 ociation to AV complete visualization rates (p = 0.30 and p = 0.14).

78 clinically relevant bleeding (4.8% vs. 2.9%, p = 0.34) or major bleeding (3.6% vs. 1.6%, p = 0.18).

79 hotography, fundus autofluorescence, or OCT (P = 0.35-0.99).

80 of glaucoma, including open-angle glaucoma (P = 0.36), chronic angle closure glaucoma (P = 0.85) and

81 c angle closure glaucoma (P = 0.85) and OHT (P = 0.42).

82 4.4 mmHg (n = 29, P = 0.519) on 2.0 +/- 1.6 (P = 0.457) glaucoma medications.

83 the mean IOP was 12.6 +/- 4.4 mmHg (n = 29, P = 0.519) on 2.0 +/- 1.6 (P = 0.457) glaucoma medicatio

84 he active group and 36.4% in the sham group (P = 0.6).

85 , 1.092; p = 0.059] and 1.008 [0.966, 1.052; p = 0.702], respectively).

86 (P = 0.36), chronic angle closure glaucoma (P = 0.85) and OHT (P = 0.42).

87 han in those that did not (0.48 [0.16-0.80], p=0.002), and lower in clusters that received rfMDA plus

88 .9%; hazard ratio, 1.60 [95% CI, 1.15-2.22]; P=0.005).

89 those receiving RACD only (0.26 [0.10-0.68], p=0.006).

90 ncidence rate ratio 0.52 [95% CI 0.16-0.88], p=0.009), lower in clusters receiving RAVC than in those

91 ss often than younger children (29% vs. 48%; p=0.01) or adolescents (29% vs. 60%; p<0.0001).

92 rtemisinin-piperaquine (eight [1.5%] of 543; p=0.012).

93 those who remained negative (21.8% vs 8.5%, p=0.01; OR 3.0, 95%CI 1.31-6.87).

94 (45+/-14 versus 49+/-16 years, respectively; P=0.04).

95 15.5%; adjusted HR=0.85 [95% CI, 0.72-1.00], P=0.05).

96 eal evidence of a significant discontinuity (P=0.66).

97 he accumulated dose of gadoterate meglumine (P=0.9064; rho=-0.0164 [95%]).

98 (P = .0044) and hyperplastic blood vessels (P = .0005).

99 elf-efficacy (aOR, 2.38; 95% CI, 1.54, 3.67, P = .001) were positively associated with ApoL1 test int

100 in genetics (aOR, 2.89; 95% CI, 1.95, 4.29, P = .001), and genetics self-efficacy (aOR, 2.38; 95% CI

101 n scores (P < .0001), forced vital capacity (P = .0017), FEV(1) (P = .037), and total lung capacity (

102 1.7; 95% confidence interval [CI]: 1.2, 2.4; P = .002) and osseous metastases (RR: 1.9; 95% CI: 1.6,

103 ment-emergent nephrotoxicity in 10% and 56% (P = .002), respectively.

104 ess in GBM, particularly tumor infiltration (P = .0044) and hyperplastic blood vessels (P = .0005).

105 ll 3 sets of blood cultures (15.4% vs 45.1%; P = .005) and had less severe clinical presentations (me

106 methylation (aOR, 6.49 [95% CI, 1.66-25.35], P = .007), but not significantly higher in women with po

107 5; 95% confidence interval [CI], 1.18, 2.60, P = .01), AA identity (aOR, 1.67; 95% CI, 1.02, 2.72, P

108 sis had higher glutamate levels in thalamus (p = .01), but Glx levels in dorsal ACC and thalamus did

109 fference, -0.37% [95% CI, -0.66% to -0.08%]; P = .01).

110 FEV(1) (P = .037), and total lung capacity (P = .013) but not their lung carbon monoxide diffusion c

111 was associated with higher TNF-alpha levels (P = .013).

112 [95% confidence interval {CI}, 1.27-29.18], P = .02) and with positive cervical methylation (aOR, 6.

113 bution hazard ratio, 9.0; 95% CI, 1.50-54.0; P = .02) was independently associated with post-HCT AIC.

114 seous metastases (RR: 1.9; 95% CI: 1.6, 2.3; P = .02); RB1 mutation (seen in 19 of 103 patients, 18.4

115 ents had lower levels of GABA in dorsal ACC (p = .03), and the subgroup of patients with a schizophre

116 ing donation (aOR, 1.68; 95% CI, 1.03, 2.73, P = .03), interest in genetics (aOR, 2.89; 95% CI, 1.95,

117 l carcinomatosis (RR: 5.9; 95% CI: 3.8, 9.2; P = .03).

118 old lower during the follow-up year (n = 18, P = .03).

119 , forced vital capacity (P = .0017), FEV(1) (P = .037), and total lung capacity (P = .013) but not th

120 0-2] in patients with any positive BDG test; P = .039).

121 AA identity (aOR, 1.67; 95% CI, 1.02, 2.72, P = .04), perceived kidney disease risk following donati

122 < .001 vs control) and HBsAg seroconversion (P = .046 vs control).

123 nted fixation; HR, 0.95 [95% CI, 0.90-1.01]; P = .08).

124 ificant after adjusting for career duration (P = .083, .459, and .113, respectively).

125 en the 2 treatment arms was not significant (P = .09).

126 ltivariable model including the ALL subtype (P = 1.1 x 10-14), the SLC19A1/(ABCC1 + ABCC4) transporte

127 42% of the variation in MTXPG accumulation (P = 1.1 x 10-38).

128 tio (P = 3.6 x 10-4), the MTX infusion time (P = 1.5 x 10-3), FPGS mRNA expression (P = 2.1 x 10-3),

129 ns associated with response or resistance to PD-1 blockade.

130 sponses using checkpoint inhibitors, such as PD-1 or PD-L1 inhibitors.

131 nts (100%) received prior ICIs targeting the PD-1 pathway.

132 demonstrated synergy when combined with anti-PD-1 therapy.

133 immunotherapy with programmed cell death-1 (PD-1) checkpoint blockade.

134 TLA-4), 2542 per 100 000 for nivolumab (anti-PD-1), 2451 per 100 000 for pembrolizumab (anti-PD-1), 5

135 1), 2451 per 100 000 for pembrolizumab (anti-PD-1), 5556 per 100 000 for ipilimumab plus nivolumab, a

136 point intervention, we quantitatively imaged PD-1/PD-L1 interactions in tumor samples from patients,

137 eir lung carbon monoxide diffusion capacity (P = .12).

138 mildly increase (3% bezafibrate, 5% placebo, P = .14).

139 an be considered as a bicapped derivative of Pd(16) with a tetra-palladium-oxo unit grafted on either

140 ng to a submicron gradient of activated CtrA-P(19) that is stable and sublinear.

141 -binding protein PC4, in complex with a full PS 2'-OMe DNA gapmer ASO.

142 time (P = 1.5 x 10-3), FPGS mRNA expression (P = 2.1 x 10-3), and MTX systemic clearance (P = 4.4 x 1

143 x 10(-8)) and in the transgenic sheep model (p = 2.4 x 10(-88)).

144 ociated with altered white matter integrity (p = 2.5x10-7) in brain images from 1,738 young healthy a

145 Pd(24) O(44) (OH)(8) ((CH(3) )(2) As)(16) ] (Pd(24) ) can be considered as a bicapped derivative of P

146 The 24-palladium(II)-oxo cluster [Pd(24) O(44) (OH)(8) ((CH(3) )(2) As)(16) ] (Pd(24) ) ca

147 ntly higher abundance (43%), richness (32%), PD (25%) and FD (25%) of birds visiting polyculture plot

148 vivors treated with 0 < CED < 4,000 mg/m(2) (P = 3.1 x 10(-4)) and 24 male survivors treated with CED

149 e SLC19A1/(ABCC1 + ABCC4) transporter ratio (P = 3.6 x 10-4), the MTX infusion time (P = 1.5 x 10-3),

150 h AF was more significant (odds ratio, 6.15, P=3.26x10(-14)) when restricting to LOF variants located

151 tion compared with 25.0% postimplementation (P = .32).

152 P = 2.1 x 10-3), and MTX systemic clearance (P = 4.4 x 10-2) explained 42% of the variation in MTXPG

153 90; 95% confidence interval [CI], 1.60-2.25; P = 5.88 x 10(-13)).

154 icated in the Q175 Htt knock-in mouse model (p = 6.0 x 10(-8)) and in the transgenic sheep model (p =

155 nted fixation; HR, 0.94 [95% CI, 0.73-1.21]; P = .61) and overall mortality (cumulative incidence at

156 fferent carrot cultivars when parasitized by P. aegyptiaca.

157 hese results shed light on how mucus impacts P. aeruginosa behavior, and may inspire novel approaches

158 We used a diverse set of 58 complete P. aeruginosa genomes to curate a set of 4,440 core gene

159 may inspire novel approaches for controlling P. aeruginosa infections.

160 Among the P. aeruginosa isolates, 2 (6.9%) VMEs and 3 (3.3%) MEs w

161 outer membrane perturbation can be sensed by P. aeruginosa to activate the T6SS even when the disrupt

162 antly associated with 90-day mortality were: P: age, gender and ACLF type; I: drug, infection, surger

163 RNase P and MRP are highly conserved, multi-protein/RNA comple

164 cal processes.IMPORTANCE Phosphatidylserine (PS) and phosphatidylethanolamine (PE) are usually seques

165 TNNI3 p.Arg21Cys-related cardiomyopathy manifested a malignant

166 Probing depth (PD), attachment level, bleeding on probing (BOP), and in

167 ear mixed models, including biomarker [log10(P/B ratio) and/or AMY1 CN] diet-group interactions.

168 N(theta) clusters had deteriorated with p < p(Cluster), chosen empirically to give 95% specificity b

169 Among the RTO compounds, p-cymene and thymol were the most abundant in packed box

170 hat inhibitory phosphorylation of eIF2alpha (P-eIF2alpha), a conserved translation initiation factor,

171 ent (61/92 [66%] vs 84% [391/465] P < 0.001, P for interaction by regimen 0.49).

172 SD), and mean VF sectoral pattern deviation (PD) from SD OCT data.

173 d the three echocardiography gating methods (p > 0.05 for all).

174 etes or obesity when compared to no-CCY (all P > 0.05), but were less likely to have a previous C-sec

175 as all crashes or at-fault crashes only (all p > 0.05).

176 mpact on DeltaRNFL in the opposite quadrant (P > 0.05).

177 Performance was equivalent (P > 0.48) to bulk stool for all targets when 50 mul of F

178 fective than TIV in preventing all-cause and P&I hospitalization from NHs during an A/H3N2 predominan

179 n liver and spleen at day 5 postinfection (d p.i.), although both wild-type and DUBmut virus infectio

180 actors that regulate stimulation-dependent E-P interactions.

181 "do not eat me" signal for macrophages) and PD-L1 (a T-cell inactivator) on their surface.

182 rtoire of sebocytes, notably by upregulating PD-L1 and IL10.

183 ell lines and 4T1 mouse mammary tumor cells, PD-L1 expression was regulated by the nuclear receptor N

184 imal germinal center (GC)-rich region of the PD-L1 gene promoter.

185 using checkpoint inhibitors, such as PD-1 or PD-L1 inhibitors.

186 intervention, we quantitatively imaged PD-1/PD-L1 interactions in tumor samples from patients, emplo

187 HRs) were reviewed for individuals harboring P/LP variants who were predicted to develop disease (G+)

188 The submitted variant set included 28 P/LP variants, 96 VUS, and 34 LB/B variants, mostly in c

189 therapy improved patients' HRCT scan scores (P < .0001), forced vital capacity (P = .0017), FEV(1) (P

190 l group, 11.8 metabolic equivalents +/- 5.5; P < .0001).

191 ups had decreases in HBsAg to below 1 IU/mL (P < .001 vs control) and HBsAg seroconversion (P = .046

192 ts with PXS and normal control subjects (all P < .001) without a difference between PXS and control e

193 s yielding statistically significant values (P < .001).

194 143 died (4%) vs 362 of 2095 patients (17%, P < .001).

195 31 cases/100 000 person-years, respectively; P < .001).

196 ate-, and adverse-risk groups, respectively (P < .001).

197 was greater vitreous echodensity (R: 0.573; P < .01) and degradation in CSF (R: 0.611; P < .01).

198 survival (adjHR, 1.83; 95% CI, 1.15 to 2.92; P < .01) and overall survival (adjHR, 2.04; 95% CI, 1.22

199 survival (adjHR, 2.04; 95% CI, 1.22 to 3.40; P < .01).

200 ; P < .01) and degradation in CSF (R: 0.611; P < .01).

201 ignificantly increase the odds of rejection (P < .1).

202 arly/mild ILA at enrollment (63.3% vs. 6.1%; P < 0.0001).Conclusions: Rare and common environmental e

203 pathological regression (TRG1-2 = 44% vs 8%, P < 0.001) and a trend to tumor downstaging as compared

204 0.77; 95% confidence interval: 0.68 to 0.88; p < 0.001) and all-cause-mortality (7.6% vs. 9.7%; adjus

205 SD age: 67.8 +/- 8.9 vs. 66.1 +/- 8.2 years; p < 0.001) and more likely to have diabetes mellitus (p

206 62% lower mortality risk (aHR: 0.310.380.46, P < 0.001) beyond this.

207 owed that there were significant variations (p < 0.001) for all assessed quantitative traits.

208 8; p < 0.001) for NHB, 2.8 (95% CI 2.7, 3.0; p < 0.001) for Hispanic, 2.2 (95% CI 1.8, 2.6; p < 0.001

209 < 0.001) for Hispanic, 2.2 (95% CI 1.8, 2.6; p < 0.001) for NHAIAN, and 1.6 (95% CI 1.4, 1.7; p < 0.0

210 0.001) for NHAIAN, and 1.6 (95% CI 1.4, 1.7; p < 0.001) for NHAP populations.

211 s relative to NHW were 3.6 (95% CI 3.5, 3.8; p < 0.001) for NHB, 2.8 (95% CI 2.7, 3.0; p < 0.001) for

212 aried from 59 (US) to 69 mm (Nancy, France) (p < 0.001), 25.3% of patients having a diameter of < 60

213 ompared to those without PDR (85% [605/713], P < 0.001), and for those on EFV-based treatment (60% [1

214 < 0.001), increased mucosal thickness (34%; P < 0.001), and increased epithelial cell density (13%;

215 (adjusted hazard ratio [aHR]: 2.493.494.89, P < 0.001), but a 62% lower mortality risk (aHR: 0.310.3

216 changes, including increased branching (59%; P < 0.001), increased mucosal thickness (34%; P < 0.001)

217 0.001; <= 1 consecutive days: 0.68 d fewer, p < 0.001).

218 vs. SLT, 19.0%; RR, 1.37; 95% CI, 1.33-1.42; P < 0.001).

219 vs. 0.83 [95% CI, 0.69-0.93], respectively; P < 0.001).

220 r than in the HMS group (27.6 vs. 17.0 mmHg, P < 0.001).

221 erlipidemia, and chronic kidney disease (all p < 0.001).

222 (>0.11 ml(-1) OR 3.067, 95% CI 1.825-5.128, p < 0.001).

223 ow-severity cases (0.98 vs 0.40 events/case, P < 0.001).

224 ed by type 2 MI (34.2%) and type 1 MI (12%) (p < 0.001).

225 ard ratio [HR], 3.05 [95% CI, 1.65 to 5.62]; P < 0.001).

226 0.61; 95% confidence interval: 0.53 to 0.71; p < 0.001).

227 n, day 2: 40.9% +/- 9.7% vs. 59.2% +/- 4.4%, P < 0.001).

228 and increased epithelial cell density (13%; P < 0.001).

229 significantly outperformed using DCE alone (P < 0.001).

230 om 40% of TEVARs in the US to 72% in the UK (p < 0.001).Mean intact TAA (iTAA) diameter varied from 5

231 ased treatment (61/92 [66%] vs 84% [391/465] P < 0.001, P for interaction by regimen 0.49).

232 p = 0.010; 2 consecutive days: 0.77 d fewer, p < 0.001; <= 1 consecutive days: 0.68 d fewer, p < 0.00

233 [p = 0.02]) and two families (Moraxellaceae [p < 0.001] and Pseudomonadaceae [p = 0.01]).

234 ly associated with SO2 (1.207 [1.154, 1.262; p < 0.001]) but not significantly associated with NO2 an

235 1.082; p = 0.017], and 1.190 [1.146, 1.235; p < 0.001], respectively) when highest and lowest pollut

236 offs resulting in statistically significant (P < 0.005) differences between benign and malignant lesi

237 ed with an 11.0% point (95% CI: -18.1, -3.8; P < 0.01) adjusted relative reduction in anemia prevalen

238 y associated with Braak stage (|rho| > 0.45, P < 0.01) and Thal phase (rho > 0.55, P < 0.01), respect

239 mg/L (IQR: 83-179) vs 73 mg/L (IQR: 12-98), P < 0.01), lactate [1.1 mmol/L (IQR: 1.0-1.6) vs 4.6 mmo

240 0.45, P < 0.01) and Thal phase (rho > 0.55, P < 0.01), respectively.

241 p = 0.02) and less often asthma (8% vs 23%; p < 0.01).

242 assessment (89.45 [19.32] vs 110.10 [19.54]; p < 0.01).

243 xygen [25% (IQR: 21-31) vs 42% (IQR: 30-80), P < 0.01] differed between survivors and non-survivors.

244 (IQR: 1.0-1.6) vs 4.6 mmol/L (IQR: 2.8-8.0), P < 0.01], and fraction of inspired oxygen [25% (IQR: 21

245 nd Latino Americans, respectively (age trend P < 0.05 and interaction P = 0.041).

246 ociated with higher levels of Porphyromonas (p < 0.05) and Prevotella.

247 e had a statistically significant reduction (P < 0.05) in viral titer in liver and spleen at day 5 po

248 allic, and ferulic acids were significantly (p < 0.05) increased in FIR dried samples.

249 e same model, apoB retained a robust effect (p < 0.05), whereas the estimate for LDL cholesterol was

250 els, in comparison to DM+INS and DM+RSV+INS (P < 0.05).

251 s (diet/exercise) than the usual care group (P < 0.05).

252 d higher short- and long-term mortality (all P < 0.05).

253 family-wise error rate (FWER) significance (p < 1.25E-06).

254 We found 41 loci associated (P < 5 x 10(-8)) with left-handedness and 7 associated wi

255 f >= N(theta) clusters had deteriorated with p < p(Cluster), chosen empirically to give 95% specifici

256 psia/eclampsia or be in the third trimester (P <= 0.01).

257 were most relevant to both classifications (p <= 0.044).

258 DBG/HV when compared with the other groups (P <=0.05).

259 s. 48%; p=0.01) or adolescents (29% vs. 60%; p<0.0001).

260 symptoms and care partner physical (B=0.05, P<0.001) and psychological (B=0.04, P<0.001) QOL.

261 (B=0.05, P<0.001) and psychological (B=0.04, P<0.001) QOL.

262 to young children (OR:2.71, 95%CI 1.51-5.02, p<0.001), and among asymptomatic controls with presence

263 ] EVR versus $31 442 [$24 669-$40 419] open; P<0.001), driven by a lower rate of in-hospital complica

264 measured by ELISA (R(2)=0.67 by Marburg VN; p<0.001).

265 l complications (6.6% EVR versus 38.0% open; P<0.001).

266 yfunctionality score in group 1 vs group 4b, p<0.01).

267 logy and survivor psychological QOL (B=0.03, P<0.05) and moderated the association between care partn

268 ovirus infection (OR:4.23; 95%CI 1.16-14.22, p<0.05).

269 recipients with no late boost (all adjusted p<0.05, except for the polyfunctionality score in group

270 rate that simultaneous recognition of PE and PS maximizes PS receptor-mediated virus entry and effero

271 and effective method for preparing amorphous Pd nanomaterials, and demonstrates their promising elect

272 Cebranopadol at a low dose of 25 ug/kg (p.o.) did not induce significant hyperactivity itself, b

273 ctrophysiological effects of native (WT) and p.P888L SAP97, a common polymorphism.

274 Parkinson's disease (PD) pathogenesis may involve the epigenetic control of e

275 The pH, the ZnSO(4)/PS ratio, and ions and quenchers, were investigated.

276 ultaneous recognition of PE and PS maximizes PS receptor-mediated virus entry and efferocytosis and u

277 P-Rex1 has also become increasingly recognized for its r

278 3) to the pleckstrin homology (PH) domain of P-Rex1 is required for its activation in cells.

279 nitrogen-doped carbon (M(1)/CN, M = Pt, Ir, Pd, Ru, Mo, Ga, Cu, Ni, Mn).

280 ease onset, were collated to produce a DELTA-P score for each patient.

281 ere within +/-10 ppm (mass error) and with a P-Score <=1 x 10(-04).

282 0 proteins and 55,000 phosphorylation sites (p-sites) from 125 CCLs.

283 the isomer (C(6)H(4), O)(C, N, Ph) formed by P-stereomutation involving a M(B2) permutational mechani

284 HopO1-1 is required for P. syringae to spread locally to neighboring tissues dur

285 rowing body of evidence in the use of plasma p-tau181 as a non-invasive diagnostic and prognostic too

286 positive transcription elongation factor b (P-TEFb), composed of CDK9 and cyclin T, stimulates trans

287 orm alternative to the native fold for RNase P to bind and mature SRP RNA co-transcriptionally.

288 multivariable HR of 0.84 (95% CI, 0.70-0.99; P trend = 0.04) for the proximal colon cancer incidence.

289 r findings demonstrated the effectiveness of P-Tris affinity nanofiber membrane for the recovery of l

290 The most frequently broken motif was REST (p value = 0.0028), which has been reported as both a tum

291 ciated with severe asthma exacerbations at a P value of .01 or less in the same direction of associat

292 d with the number of courses of antibiotics (P-value > 0.05), but it was significantly associated wit

293 th increased number of postoperative visits (P-value < 0.05).

294 Adjusted odds ratios (95% CI; p-value) for infant deaths were significantly increased

295 95 [95% CI: 1.55 to 2.45] for the PNI score; p values <0.001 for all nutritional indexes).

296 year-olds (respective aRRs 1.79, 2.33, 1.92; p-values <= 0.002).

297 metagenome sequence data is significant with P-values less than 4.04E-17.

298 However, testing this is challenging because P varies within landscapes as a function of geology, top

299 Circumsporozoite protein (CSP) variants of P. vivax, besides having variations in the protein repet

300 Compared with HDL-C, HDL-P was consistently associated with MI and ischemic strok